Bedrijfsoverzicht
Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company dedicated to the development of therapeutics targeting rare diseases in the liver and respiratory systems. The organization operates within the Healthcare sector, specifically focusing on the Biotechnology industry, a field characterized by high research and development costs and reliance on proprietary intellectual property to bring novel treatments to market. As a mid-cap entity, the company reports a market capitalization of $237.62M and generates annual revenue of $82.03M based on trailing twelve-month figures. The workforce supporting these operations consists of 106 employees, indicating a lean organizational structure typical for early-to-mid stage biotechnology firms. The combination of a market cap under $500M and revenue below $100M suggests the company is still establishing its commercial footprint and validating its technology platforms, such as the STARR self-amplifying mRNA technology and the LUNAR lipid-mediated delivery system, before achieving sustained profitability. This scale places the company in a phase where cash reserves are critical for funding clinical trials and expansion rather than dividend generation or significant shareholder returns.
Financiële gezondheid
The financial performance of Arcturus Therapeutics Holdings Inc. shows a revenue of $82.03M for the trailing twelve months, contrasted with a net income of $-65,783,000 and an EBITDA of $-73,235,000. The significant gap between positive revenue and substantial negative net income reveals a cost structure dominated by high operating expenses, likely driven by research and development activities essential for bringing mRNA therapies to clinical approval. Despite the net loss, the company maintains a positive free cash flow of $9.18M, which provides essential financial flexibility to fund ongoing operations and development programs without needing immediate external equity financing. The gross margin stands at -36.8%, while the operating margin is -435.1% and the profit margin is -80.2%; these negative figures indicate that current operational costs, including R&D and manufacturing, exceed gross revenues, a common characteristic in the biotechnology sector during pre-commercialization stages. Regarding leverage, the company holds $230.91M in cash against $25.00M in debt, resulting in a debt-to-equity ratio of 11.68, which reflects a highly conservative balance sheet where cash significantly outweighs obligations despite the high debt-to-equity metric often seen in cash-rich but loss-making biotech firms. Liquidity is further supported by a current ratio of 6.64, indicating that the company possesses more than six times the current assets needed to cover its short-term liabilities, ensuring robust short-term solvency. The return on equity is -28.9% and the return on assets is -15.5%, metrics that reveal that management is currently deploying capital into growth initiatives that have not yet generated positive returns, resulting in negative efficiency ratios typical for companies in the development phase of their product lifecycle.
Waarderingsbeoordeling
Valuation metrics for Arcturus Therapeutics Holdings Inc. present a complex picture due to the lack of traditional profitability indicators. The trailing P/E ratio is N/A because the company has not generated positive net income over the trailing twelve months, while the forward P/E is reported as -1.99, implying that future earnings expectations remain negative in the immediate forecast horizon. The price-to-book ratio is 1.11, suggesting that the market values the company at a slight premium over its book value, which may reflect the potential value of its intellectual property and pipeline assets not fully captured on the balance sheet. Alternative valuation multiples provide additional context; the price-to-sales ratio is 2.90 and the EV/EBITDA is -0.43, indicating that investors are pricing the company primarily on its revenue generation capabilities rather than earnings power. Price action over the last year shows a 52-week high of $24.17 and a 52-week low of $5.85; without a specific current price provided in the available facts, the valuation is assessed relative to this wide trading range which highlights the stock's high sensitivity to market sentiment and clinical trial outcomes. The beta value of 2.44 indicates that the stock's price volatility is significantly higher than that of the broader market, moving approximately 2.44 times as much as the market index during periods of fluctuation.
Growth & Income
The growth profile of Arcturus Therapeutics Holdings Inc. is defined by a revenue growth rate of -68.4% year-over-year, while earnings growth is N/A due to the absence of prior period profits. The negative revenue growth indicates a contraction in sales, likely attributable to the company's strategic focus on developing new therapeutics rather than scaling existing commercial sales of approved products. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available cash flow and retained earnings back into its research and development pipeline to pursue future growth opportunities. This lack of dividend distribution is standard for biotechnology firms that prioritize funding clinical trials and manufacturing scale-up over providing current income to shareholders. The overall growth and income profile is characterized by a contraction in top-line revenue coupled with a complete absence of income distribution, reflecting a business model focused entirely on long-term asset creation through the successful development of its mRNA medicines for rare liver and respiratory diseases.